Pfizer’s presence at ASCO 2023
TALZENNA® + XTANDI® in patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).
Find Out MoreBRAFTOVI® + MEKTOVI® significantly improves objective response rates in metastatic non-small cell lung cancer (NSCLC).
Find Out MoreWe are presenting updated data from our comprehensive MagnetisMM multiple myeloma clinical development program across 13 abstracts.
Find Out MoreOur presented data spans 15+ therapies across 10+ types of cancer, including six early pipeline medicines.
Read Our Press ReleaseOur commitment to advancing scientific innovation will be displayed with 40+ accepted abstracts from our growing oncology portfolio.
See Our Abstract ListOver the past decade, we’ve taken bold new approaches to translate scientific research into effective medicines for people living with cancer.
Learn MorePress Releases
All Pfizer published press releases by date and/or category of news
06.01.2023 Phase 3 Studies of Pfizer’s Novel Antibiotic Combination Offer New Treatment Hope for Patients with Multidrug-Resistant Infections and Limited Treatment Options 05.31.2023 Vaccines Vaccines U.S. FDA Approves ABRYSVO™, Pfizer’s Vaccine for the Prevention of Respiratory Syncytial Virus (RSV) in Older Adults 05.30.2023 Research and Pipeline Pfizer Announces Positive Marstacimab Results from Pivotal Phase 3 Hemophilia A and B Trial
Media Asset Library
A collection of assets for use by media.
Partnering News
The latest news from Pfizer and its strategic partners
05.08.2023 Corporate Partnerships Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentations at the 2023 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress 01.06.2023 Corporate Partnerships Longevity Biotech Gero Entered a Research Collaboration with Pfizer to Discover Potential Targets for Fibrotic Diseases
Media Contacts
Pfizer Media Relations
We encourage everyone to view our press releases, press statements, and press kits to stay up to date on Pfizer news.
However, to ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.
Media Contacts
General email
[email protected]
United States, Canada and Latin America
+1 212.733.1226
Europe, the Middle East and Africa
+44-(0)173.733.2335
[email protected]
Asia Pacific
+65.918.732.47
What we need
To best help us help you, please be prepared to provide your name and email address, a summary of the article you're working on and your deadline.
Other Frequently Visited Links
For more, see these helpful and often used sections of Pfizer.com
Pfizer Wire
Stay up to date on the latest news and alerts through the Pfizer Wire
Sign up to receive real-time updates on Pfizer’s news from the Pfizer Media Relations team delivered directly to your inbox.